A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in AdultPatients with Cystic Fibrosis
A study for patients with Cystic Fibrosis using oral study drug CTX-4430
Sponsor: Celtaxsys
Enrolling: Male and Female Patients
IRB Number: AAAQ8534
U.S. Govt. ID: NCT02443688
Contact: Emily DiMango: 212-305-0631 / ead3@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to look at the effectiveness, safety, and tolerability of study drug CTX-4430 when compared to a placebo (sugar pill) taken once-daily for 48 Weeks in adult patients with CysticFibrosis (CF).
This study is closed
Investigator
Emily DiMango, MD
Do You Qualify?
Have you been diagnosed with Cystic Fibrosis (CF)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Emily DiMango
ead3@cumc.columbia.edu
212-305-0631
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE